Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Daclizumab in Relapsing-Remitting MS

Assessing its effect on health-related quality of life

Publish date:: February 16, 2016

Daclizumab high-yield process (DAC HYP) 150 mg improved health-related quality of life (HRQoL) in patients with relapsing-remitting multiple sclerosis (RRMS) compared to placebo. This according to analysis of patient-reported outcomes in the SELECT clinical trial. Researchers found:

DAC HYP 150 mg had a significantly positive effect on HRQoL vs placebo.

It also significantly reduced the adverse impact of relapse on the MSIS-29 physical scale.

Relapse and disease progression were significantly associated with impaired HRQoL.

Citation: Phillips G, Guo S, Bender R, Havrdová E, Proskorovsky I, Vollmer T. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. [Published online ahead of print February 1, 2016]. Mult Scler Rel Dis. doi: 10.1016/j.msard.2016.02.001.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,